Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

  title={Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.},
  author={Haiying Qin and Monica Cho and Waleed M. Haso and Ling Zhang and Sarah K Tasian and Htoo Zarni Oo and Gian Luca Negri and Yongshun Lin and Jizhong Zou and Barbara S. Mallon and Shannon L Maude and David Teachey and David M Barrett and Rimas J. Orentas and Mads Daugaard and Poul H. B. Sorensen and Stephan A. Grupp and Terry J Fry},
  volume={126 5},
Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting the CD19 B cell-associated protein have demonstrated potent activity against relapsed/refractory B-lineage acute lymphoblastic leukemia (B-ALL). Not all patients respond, and CD19-negative relapses have been observed. Overexpression of the thymic stromal lymphopoietin receptor (TSLPR; encoded by CRLF2) occurs in a subset of adults and children with B-ALL and confers a high risk of relapse… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 14 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 22 extracted citations


Publications referenced by this paper.
Showing 1-10 of 51 references

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

  • MS Topp, N Gokbuget, G Zugmaier
  • J Clin Oncol
  • 2014

Similar Papers

Loading similar papers…